Big Pharma Split Corp.
PRM.TO · TSX
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.01 | -0.00 | 1.22 |
| FCF Yield | 6.77% | -5.80% | -2.41% | -2.42% |
| EV / EBITDA | 0.00 | -17.24 | 17.70 | -95.41 |
| Quality | ||||
| ROIC | -4.72% | -5.72% | 5.43% | 1.62% |
| Gross Margin | 100.00% | 79.09% | 85.44% | 100.00% |
| Cash Conversion Ratio | -1.79 | 0.49 | -0.34 | 10.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -37.09% | -11.29% | -15.90% | -7.52% |
| Free Cash Flow Growth | 199.65% | -106.92% | 46.58% | -314.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -7.10 | 6.06 | -22.55 |
| Interest Coverage | -3.90 | -5.07 | 5.64 | 0.69 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.21 |
| Cash Conversion Cycle | -10.12 | 11.84 | 4.97 | -574.59 |